MedCity News June 5, 2024
Novo Nordisk’s focus on diabetes and obesity shape its business development work, but the company is also exploring other areas. Top Novo Nordisk M&A executive John McDonald discussed his company’s strategy during a session at the BIO conference in San Diego.
If you’re working at a biotech company in the therapeutic areas of diabetes or obesity, John McDonald might want to talk with you. McDonald is global head of business development and M&A at Novo Nordisk, a company that was one of the top dealmakers in 2023, striking 14 transactions totaling $9.5 billion in disclosed deal value.
Novo Nordisk’s dealmaking activity is continuing. Earlier this year, the company struck a multi-billion acquisition agreement to secure manufacturing capacity to support the...
Today's Sponsors
Today's Sponsor